Form 4: Castle Biosciences COO Vests, Sells Shares for Tax

Castle Biosciences Chief Operating Officer Kristen M. Oelschlager reported the vesting and subsequent sale of company common stock for tax purposes.

Summary

• Chief Operating Officer Kristen M. Oelschlager reported transactions involving Castle Biosciences common stock.
• On December 9, 2025, 15,961 Restricted Stock Units (RSUs) vested and converted into common stock.
• Concurrently, 4,691 shares were sold at $38.25 per share to cover tax obligations related to the RSU vesting.
• On December 10, 2025, an additional 6,170 RSUs vested and converted into common stock.
• 2,552 shares were sold at $38.02 per share on December 10, 2025, for tax withholding.
• Following these transactions, Oelschlager directly holds 27,211 shares and indirectly holds 97,251 shares through The Fritz Shorter Trust.

Sentiment

Score: 6

Explanation: The filing reports routine vesting of restricted stock units and subsequent sales for tax withholding purposes by a company officer, indicating normal equity compensation activity without significant positive or negative implications for company operations or outlook.

Positives

• The vesting of Restricted Stock Units indicates the maturation of long-term incentive plans for the Chief Operating Officer, aligning management interests with shareholder value over time.

Negatives

• The sale of shares, even for tax purposes, results in a reduction of the Chief Operating Officer's direct beneficial ownership in the company.

Future Outlook

This filing is a disclosure of past transactions and does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

This filing details routine insider transactions related to equity compensation, which is a common practice across various industries to incentivize and retain key executives. It does not provide specific insights into broader industry trends or competitive positioning.

Related Party Transactions

• The Reporting Person indirectly holds 97,251 shares of common stock through The Fritz Shorter Trust, of which the Reporting Person and her spouse are the trustees and beneficiaries.

Stakeholder Impact

• Shareholders: The transactions represent routine insider activity related to executive compensation and are unlikely to have a significant direct impact on the broader shareholder base.
• Employees: The vesting of RSUs demonstrates the company's ongoing use of equity compensation programs, which can be a positive for employee retention and motivation.

Key Dates

Recommendation

This Form 4 filing details routine vesting of restricted stock units and subsequent sales for tax withholding by a Chief Operating Officer. Such transactions are standard for executive compensation and do not typically signal a change in company fundamentals or management's long-term outlook. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Castle Biosciences, CSTL, Form 4, Insider Transaction, Stock Vesting, RSU, Chief Operating Officer, Equity Compensation, Share Sale, Tax Withholding